Projects per year
Personal profile
Research interests
My research is situated within sociology of medicine and pharmaceuticals. My main area of interest is the transparency of interactions between drug companies, patient organisations, and the health service. In addition, I examine social processes, especially lobbying, associated with the scientific assessment as well as pricing and reimbursement of medical technologies.
I draw on key traditions in political sociology, especially the work of Marx, Weber as well as C.W. Mills, Theda Skocpol, Stephen Lukes, and G. William Domhoff. I utilise multiple research methods ranging from ethnography and in-depth elite interviews to surveys, regression analysis, and social network analysis. I also have experience in using investigative methods, such as freedom of information requests. My research often results in creating large publicly available databases, some of which can be accessed through this website.
The initial focus of my work has been on Central-European countries such as Poland, Hungary, and Slovakia. More recently, I have been examining pharmaceutical policy in the UK, with a particular focus on England, as well as Nordic countries. Beyond Europe, I have a special interest in Japan and New Zealand.
My research is frequently covered by the media, including The Sunday Times, The Independent, The Guardian, The Daily Mail, and Sky News.
Research interests
- Conflicts of interest
- Lobbying
- Transparency
- Industry self-regulation
- Pharmaceuticals
- Drug pricing and reimbursement
- Health technology assessment
Recent and current research projects
Research affiliations
- Social Science Applied to Healthcase Improvement Research (SAPPHIRE) Group
- Department of Sociology, University of Cambridge
- Institute of Sociology, University of Warsaw
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Lecturer, Department of Social & Policy Sciences
2015 → 2020
Prize Fellow, Department of Social & Policy Sciences
2013 → 2015
Research Associate, Department of Health Sciences, University of Leicester
2011 → 2013
Doctor of Philosophy, Department of Sociology, University of Cambridge
2007 → 2013
Master of Arts, Department of Sociology, University of Warsaw
2002 → 2007
Senior Lecturer , Department of Social & Policy Sciences
2020 → …
Fingerprint
- 1 Similar Profiles
Network
Projects
- 2 Finished
-
What can be learnt from the new pharmaceutical industry payment disclosures?
1/01/17 → 31/03/21
Project: Other
-
Low Visibility Tobacco Industry Political Activity and Contemporary Tobacco Regulation
Fooks, G., Gilmore, A. & Ozieranski, P.
1/07/14 → 18/12/14
Project: UK charity
-
A 'patient-industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding
Ozieranski, P., Pitter, J. G., Rickard, E., Mulinari, S. & Csanadi, M., 1 Jan 2022, In: Sociology of Health and Illness. 44, 1, p. 188-210Research output: Contribution to journal › Article › peer-review
Open Access -
Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act
Mulinari, S. & Ozieranski, P., 1 Jan 2022, In: Big Data and Society. 9, 1, p. 1-14 14 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
Pashley, D., Ozieranski, P. & Mulinari, S., 1 Mar 2022, (E-pub ahead of print) In: International Journal of Health Services. p. 207314221083871Research output: Contribution to journal › Article › peer-review
Open Access -
How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
Ozaki, A., Murayama, A., Harada, K., Saito, H., Sawano, T., Tanimoto, T. & Ozieranski, P., 3 Jan 2022, In: Frontiers in Public Health. 9, 762637.Research output: Contribution to journal › Article › peer-review
Open Access -
Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals
Main, B., Csanadi, M. & Ozieranski, P., 6 Apr 2022, (E-pub ahead of print) In: Health Economics, Policy and Law. p. 1-18 18 p.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
Dataset for "A patient-industry complex? Investigating the financial dependency of UK patient organisations on drug company funding"
Ozieranski, P. (Creator), Pitter, J. (Creator), Rickard, E. (Creator), Mulinari, S. (Creator) & Csanadi, M. (Creator), University of Bath, 7 Dec 2021
DOI: 10.15125/BATH-00904
Dataset
-
Data set for "A hidden web of policy influence: The pharmaceutical industry’s engagement with UK’s All-Party Parliamentary Groups"
Rickard, E. (Creator) & Ozieranski, P. (Creator), University of Bath, 28 May 2021
DOI: 10.15125/BATH-00943
Dataset
-
Underreporting of drug industry payments to patient organisations in the UK (2012-2016)
Ozieranski, P. (Creator), Csanadi, M. (Creator), Rickard, E. (Creator) & Mulinari, S. (Creator), University of Bath, 10 Jul 2020
DOI: 10.15125/BATH-00784
Dataset